Evaluation of Serum ficolin-2, Sialic Acid, and High Sensitivity C - reactive Protein in Patients with Multiple Sclerosis


  • Lara Balasim Ibrahim
  • Mohammed A. Mohammed Ali Al-Nahrain university, Medical College/ department of Chemistry and Biochemistry http://orcid.org/0000-0002-6953-5551
  • Akram Mohammed Al Mahdawi


Ficolin-2, Sialic acid, high sensitivity C-reactive protein, Multiple sclerosis, progression


the aim of the present study was to evaluate inflammatory blood markers in multiple sclerosis (MS) and to evaluate them with its clinical progressive forms. This study included 60 MS patients (35 with relapsing-remitting MS (RRMS) and 25 with progressive MS clinical forms) and 30 healthy individuals. Peripheral blood samples were obtained to determine serum levels of ficolin-2, high sensitivity C-reactive protein (hs-CRP), and total sialic acid (SA).  Average level of ficolin-2 in MS group was lower (29.35 + 19.88µmol/L) in comparison to (45.17 + 17.39 µmol/L) in the control group this difference appeared highly significant (p<0.0001). Mean levels of sialic acid and hs-CRP were significantly higher in the MS group (2.334+0.7046µmol/L) and (31.15 + 12.4326) respectively, as compared to the controls (1.468+0.7046 µmol/L) (20.1416+4.2496 µmol/L) (p <0.001). Furthermore, Ficolin-2 levels inversely correlated significantly with severity of the disease as measured by EDSS, this correlation has shown to be positive in regard to hs-CRP and Sialic acid.

In the logistic regression, ficolin-2 and hs-CRP showed positive association with MS and were predictors of MS development. SA, were negatively associated with MS (p< 0.0001). Using this regression analysis, 83.33% of all subjects were correctly classified with a sensitivity of 86.67% and a specificity of  76.67%. In conclusion, SA was predictor of MS diagnosis, whereas ficolin-2 and hs-CRP was predictor that differentiated RRMS from the progressive clinical forms of MS.

Author Biography

Mohammed A. Mohammed Ali, Al-Nahrain university, Medical College/ department of Chemistry and Biochemistry

Department of Chemistry and Biochemistry


Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017 Jan;13(1):25–36.

Levin LI. Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis. JAMA. 2005 May;293(20):2496.

Meinl E, Krumbholz M, Derfuss T, Junker A, Hohlfeld R. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci. 2008 Nov;274(1–2):42–4.

Tremlett H, Dai DLY, Hollander Z, Kapanen A, Aziz T, Wilson-McManus JE, et al. Serum proteomics in multiple sclerosis disease progression. J Proteomics [Internet]. 2015;118:2–11. Available from: http://dx.doi.org/10.1016/j.jprot.2015.02.018

Ciccarelli O, Barkhof F, Bodini B, Stefano N, Golay X, Nicolay K. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol [Internet]. 2014;13. Available from: http://dx.doi.org/10.1016/S1474-4422(14)70101-2

Gandhi R, Laroni A, Weiner H. Role of the innate immune system in the pathogenesis of multiple sclerosis. J neuroimmunol [Internet]. 2010;221(1–2):7–14. Available from: http://www.sciencedirect.com/science/article/pii/S0165572809004305

Ji A-L, Liu Z-H, Chen W-W, Huang W-J. The clinical significance of level changes of hs-CRP, IL-10 and TNF for patients with MS during active and relieving period. Eur Rev Med Pharmacol Sci [Internet]. 2016;20(20):4274–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27831647

Soilu-Hanninen M, Koskinen JO, Laaksonen M, Hanninen A, Lilius E-M, Waris M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology. 2005 Jul;65(1):153–5.

Ormstad H, Aass HCD, Lund-Sørensen N, Amthor KF, Sandvik L. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. J Neurol. 2011 Apr;258(4):677–85.

Széplaki G, Szegedi R, Hirschberg K, Gombos T, Varga L, Karádi I, et al. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis. 2009 May;204(1):315–20.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic Criteria for Multiple Sclerosis : 2010 Revisions to the McDonald Criteria. 2011;

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.

Wang B, Miller JB, McNeil Y, McVeagh P. Sialic acid concentration of brain gangliosides: variation among eight mammalian species. Comp Biochem Physiol A Mol Integr Physiol. 1998 Jan;119(1):435–9.

Koudriavtseva T, Mainero C. Role of Innate Immunity in Multiple Sclerosis. 2015;2(1):1–3.

Oliveira SR, Kallaur AP, Reiche EMV, Kaimen-Maciel DR, Panis C, Lozovoy MAB, et al. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis. Mol Neurobiol. 2017;54(4):2961–8.

Soilu-Hänninen M, Koskinen JO, Laaksonen M, Hänninen A, Lilius EM, Waris M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology [Internet]. 2005 Jul 12 [cited 2017 Jun 16];65(1):153–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16009907

Lindberg G, Rastam L, Gullberg B, Eklund GA. SERUM SIALIC-ACID CONCENTRATION PREDICTS BOTH CORONARY HEART-DISEASE AND STROKE MORTALITY - MULTIVARIATE-ANALYSIS INCLUDING 54385 MEN AND WOMEN DURING 20.5 YEARS FOLLOW-UP. Int J Epidemiol [Internet]. 1992 Apr 1 [cited 2017 Jun 19];21(2):253–7. Available from: https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/21.2.253

Harada H, Kai H, Shibata R, Niiyama H, Nishiyama Y, Murohara T, et al. New diagnostic index for sarcopenia in patients with cardiovascular diseases. Mogi M, editor. PLoS One [Internet]. 2017 May 18 [cited 2017 Jun 19];12(5):e0178123. Available from: http://dx.plos.org/10.1371/journal.pone.0178123

Krishnan K, Balasundaram S. Evaluation of Total and Lipid Bound Sialic Acid in Serum in Oral Leukoplakia. J Clin Diagn Res [Internet]. 2017 Mar [cited 2017 Jun 19];11(3):ZC25-ZC27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28511503

Escribano BM, Medina-Fernández FJ, Aguilar-Luque M, Agüera E, Feijoo M, Garcia-Maceira FI, et al. Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model. Neurotherapeutics [Internet]. 2017 Jan 7 [cited 2017 Jun 20];14(1):199–211. Available from: http://link.springer.com/10.1007/s13311-016-0480-0

Cho A, Christine M, Malicdan V, Miyakawa M, Nonaka I, Nishino I, et al. Sialic acid deficiency is associated with oxidative stress leading to muscle atrophy and weakness in GNE myopathy. Hum Mol Genet [Internet]. 2017 May 13 [cited 2017 Jun 20];274:19792–8. Available from: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddx192

Kilpatrick DC, Chalmers JD. Human L-Ficolin ( Ficolin-2 ) and Its Clinical Significance. 2012;2012.




How to Cite

Ibrahim, L. B., Mohammed Ali, M. A., & Mahdawi, A. M. A. (2017). Evaluation of Serum ficolin-2, Sialic Acid, and High Sensitivity C - reactive Protein in Patients with Multiple Sclerosis. Asian Journal of Applied Sciences, 5(4). Retrieved from https://ajouronline.com/index.php/AJAS/article/view/4900